AI-generated · cited to primary sources · not investment advice · How we research
Max Healthcare
Our verdict on Max Healthcare isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
53 beds have been commissioned. The timeline for the balance beds has been refined to February end, which is slightly beyond the original 2-month window from November. (3 revised, 1 met across 4 tracked commitments)
“160 beds MSSH Mohali brownfield tower: 53 beds commissioned... Balance beds will be commissioned by February end”
Tariffs were revised in mid-October and are being adopted by various institutions, with full implementation expected by April 2026. (2 in progress, 1 revised across 3 tracked commitments)
“upward revision in CGHS tariffs expected to fully kick in by April 2026”
Completion of 100-bed project at Max Nagpur. — target: 100 beds
“100 beds at Max Nagpur – We are currently awaiting formal environmental clearance... we expect to complete the project within 24 months.”
Maintain oncology revenue share at a lower level following discontinuation of high-value drugs. — target: 21-22% (+3 more commitments)
“So, I think that is the plan even going forward, that we do not expect the share of oncology come back to 25-26% as it was earlier. It will continue to hover around 21-22%, and we will then have the other specialties fill up that vacuum.”
Management expects significant operating leverage to kick in as operations ramp up following the onboarding of requisite talent for new capacities.
“Requisite talent has already been onboarded, with significant operating leverage expected to kick in as operations ramp up.”
See the full cited Management analysis of Max Healthcare
How durable is the business?
The company is further scaling its cluster approach, particularly in Noida and Lucknow, with massive land parcels (18-27 acres) allowing for potential expansion of up to 2,500 additional beds. (2 expanding)
“Similarly, in Lucknow, it is 27 acres of land. So we can go for another 2,000 - 2,500 beds there.”
Max@Home maintained steady growth at 22% YoY, though this is a slight deceleration from the previously noted 30% growth. It remains a key strategic business unit with high repeat transactions (over 50%). (5 expanding across 2 engines)
“Max@Home revenue was ₹ 73 Cr, a growth of +30% YoY and +8% QoQ. YoY growth was driven by physio & rehab, nursing care and attendants”
The clinical moat is being strengthened through the addition of advanced oncology services (radiation therapy) in units that previously lacked them, such as Dwarka and Lucknow, which is expected to drive higher ARPOB. (3 expanding, 1 shifted)
“some of the newer hospitals, particularly Dwarka and Lucknow, do not offer radiation oncology at this point... in the third quarter, we are expecting the bunkers to come through... you will see a larger share of oncology certainly in these hospitals”
International patient revenue showed strong momentum, growing 32% YoY. This segment's contribution to total revenue is increasing as the company opens direct-to-fly offices and focuses on international marketing. (2 expanding, 1 stable)
“International patient revenue reached Rs. 208 crores, registering a growth of 32% year-on-year”
International patient revenue share has slightly contracted to 8.6% of the payor mix, down from 9.1%, despite a 32% year-on-year growth in this segment. (1 contracting, 3 expanding, 1 stable)
“International [Payor Profile]: 9.1%”
See the full cited Business Model analysis of Max Healthcare
Where does growth come from?
The CGHS benefit is a new trend that is currently accelerating as the government implements new 'super specialty' codes. The expected impact has been upgraded to over INR 200 crore annually. (4 new trend across 4 signals)
“With the CGHS rate revision... the net benefit was INR 200 crore. There was also an impact of GST, so net off it the total benefit was INR 140 crore.”
Occupancy has seen a slight reversal/dip to 74% due to an 8% increase in bed capacity and a weak season for vector-borne diseases (like dengue). Management views this as a temporary seasonal blip rather than a structural decline. (1 reversing, 4 steady across 5 signals)
“Overall occupancy stood at 76% in FY26 vs 74% in FY25”
ARPOB growth appears to be decelerating on a network-wide basis (3% YoY) due to the dilution from newly acquired hospitals (Lucknow, Nagpur, Dwarka) which have a different payor mix, though existing units remain steady at ~7% growth. (2 decelerating, 3 steady across 5 signals)
“ARPOB is ₹ 77.8k vs ₹ 73.9k in FY25 (+5% YoY).”
Max Healthcare expanded its footprint into Odisha by acquiring a majority stake in the 250-bed Kalinga Hospital in Bhubaneswar. (+1 more signal)
“Acquisition of a controlling stake of 58.28% in Kalinga Hospital Ltd. (KHL) was consummated on May 18, 2026... KHL operates a 250-bed hospital on a prime 10-acre land parcel in the heart of Bhubaneswar, Odisha.”
Profitability is expected to improve as new beds ramp up, because the company has already hired the necessary staff, creating 'operating leverage' (where revenue grows faster than costs). — Operating EBITDA: 8% YoY
“We have already onboarded clinical and non-clinical talent for these capacities and expect significant operating leverage to come through as operations progressively ramp up.”
See the full cited Future Growth analysis of Max Healthcare
What could break the thesis?
The company is heavily reliant on the Delhi market for its institutional (government scheme) business, making it more vulnerable to local regulatory or pricing changes compared to competitors. [CONCENTRATION]
“Firstly, because of being in Delhi, we have a larger amount of institutional business, which was coming to our Delhi hospitals and this impacts that largely.”
Operating EBITDA per bed for the network decreased to ₹ 68 lakh in Q1 FY26 from ₹ 70 lakh in FY25, reflecting the impact of integrating new units like Dwarka and Noida. (2 intensifying, 3 easing)
“EBITDA per bed4 was ₹ 73.4 lakhs compared to ₹ 73.9 lakhs in Q4 FY25 and ₹ 71.3 lakhs in Q3 FY26”
The risk is STABLE. While the expansion is massive (1,500 beds this year), execution is on track with trial runs initiated at Mohali and advanced stages at Nanavati. However, some projects (Nagpur, Saket) are still awaiting environmental or forest clearances. (3 stable, 1 easing, 1 intensifying)
“In the past, there have been delays because of GRAP 3. We have had delays because of shortage of manpower due to the LPG crisis... pollution and shutdowns of construction or tree transplantation or Iran war causing shortage of LPG”
Net debt has increased further to INR 2,067 crore from INR 1,755 crore in the previous quarter due to ongoing deployment of capital for expansion projects (INR 456 crore this quarter). (2 intensifying, 3 easing)
“Net Debt/(Cash) Mar'26: 1,908; Mar'25: 1,576”
The risk is EASING. Management reported successful integration of recent acquisitions, with Lucknow showing 191% EBITDA growth and Nagpur growing 27% YoY, demonstrating a track record of turning around acquired assets. (4 easing, 1 emerging)
“Acquisition of a controlling stake of 58.28% in Kalinga Hospital Ltd. (KHL) was consummated on May 18, 2026... The team has already begun integration and is working towards achieving significant operational upside.”
See the full cited Risk analysis of Max Healthcare
Max Healthcare analysis by filing period
Read the full thesis on Max Healthcare
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.